 | • レポートコード：MRC2Q12-18826 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、アミバンタマブのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 アミバンタマブのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 アミバンタマブの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 アミバンタマブのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのアミバンタマブの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のアミバンタマブの売上および2028年までの予測に焦点を当てています。 アミバンタマブのグローバル主要企業には、ProteoGenix、Thermo Fisher Scientific、AntibodySystem SAS、Wuhan Chemstan Biotechnology、Biochempartnerなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 アミバンタマブ市場は、タイプとアプリケーションによって区分されます。世界のアミバンタマブ市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 0～100ug、100ug～1mg、1mg以上 【アプリケーション別セグメント】 薬学、臨床試験、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - アミバンタマブ製品概要 - タイプ別市場（0～100ug、100ug～1mg、1mg以上） - アプリケーション別市場（薬学、臨床試験、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のアミバンタマブ販売量予測2017-2028 - 世界のアミバンタマブ売上予測2017-2028 - アミバンタマブの地域別販売量 - アミバンタマブの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別アミバンタマブ販売量 - 主要メーカー別アミバンタマブ売上 - 主要メーカー別アミバンタマブ価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（0～100ug、100ug～1mg、1mg以上） - アミバンタマブのタイプ別販売量 - アミバンタマブのタイプ別売上 - アミバンタマブのタイプ別価格 ・アプリケーション別市場規模（薬学、臨床試験、その他） - アミバンタマブのアプリケーション別販売量 - アミバンタマブのアプリケーション別売上 - アミバンタマブのアプリケーション別価格 ・北米市場 - 北米のアミバンタマブ市場規模（タイプ別、アプリケーション別） - 主要国別のアミバンタマブ市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのアミバンタマブ市場規模（タイプ別、アプリケーション別） - 主要国別のアミバンタマブ市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のアミバンタマブ市場規模（タイプ別、アプリケーション別） - 主要国別のアミバンタマブ市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のアミバンタマブ市場規模（タイプ別、アプリケーション別） - 主要国別のアミバンタマブ市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのアミバンタマブ市場規模（タイプ別、アプリケーション別） - 主要国別のアミバンタマブ市場規模（トルコ、サウジアラビア） ・企業情報 ProteoGenix、Thermo Fisher Scientific、AntibodySystem SAS、Wuhan Chemstan Biotechnology、Biochempartner ・産業チェーン及び販売チャネル分析 - アミバンタマブの産業チェーン分析 - アミバンタマブの原材料 - アミバンタマブの生産プロセス - アミバンタマブの販売及びマーケティング - アミバンタマブの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - アミバンタマブの産業動向 - アミバンタマブのマーケットドライバー - アミバンタマブの課題 - アミバンタマブの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Amivantamab is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Amivantamab is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Amivantamab is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Amivantamab include ProteoGenix, Thermo Fisher Scientific, AntibodySystem SAS, Wuhan Chemstan Biotechnology and Biochempartner, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Amivantamab manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Amivantamab market. Further, it explains the major drivers and regional dynamics of the global Amivantamab market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
ProteoGenix
Thermo Fisher Scientific
AntibodySystem SAS
Wuhan Chemstan Biotechnology
Biochempartner
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by product specification and by application segments based on sales, price, and value for the period 2017-2028.
Amivantamab Segment by Product Specification
0 – 100ug
100ug – 1mg
Above 1mg
Amivantamab Segment by Application
Pharmaceutics
Clinical Testing
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Amivantamab market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Amivantamab, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Amivantamab, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Amivantamab, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Amivantamab sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Amivantamab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Amivantamab sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ProteoGenix, Thermo Fisher Scientific, AntibodySystem SAS, Wuhan Chemstan Biotechnology and Biochempartner, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Amivantamab in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Amivantamab manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by product specification, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by product specification, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by product specification, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by product specification, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by product specification, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Amivantamab sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Amivantamab Product Introduction
1.2 Market by Product Specification
1.2.1 Global Amivantamab Market Size Growth Rate by Product Specification, 2017 VS 2021 VS 2028
1.2.2 0 – 100ug
1.2.3 100ug – 1mg
1.2.4 Above 1mg
1.3 Market by Application
1.3.1 Global Amivantamab Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pharmaceutics
1.3.3 Clinical Testing
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Amivantamab Sales Estimates and Forecasts 2017-2028
2.2 Global Amivantamab Revenue Estimates and Forecasts 2017-2028
2.3 Global Amivantamab Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Amivantamab Sales by Region
2.4.1 Global Amivantamab Sales by Region (2017-2022)
2.4.2 Global Sales Amivantamab by Region (2023-2028)
2.5 Global Amivantamab Revenue by Region
2.5.1 Global Amivantamab Revenue by Region (2017-2022)
2.5.2 Global Amivantamab Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Amivantamab Sales by Manufacturers
3.1.1 Global Top Amivantamab Manufacturers by Sales (2017-2022)
3.1.2 Global Amivantamab Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Amivantamab in 2021
3.2 Global Amivantamab Revenue by Manufacturers
3.2.1 Global Amivantamab Revenue by Manufacturers (2017-2022)
3.2.2 Global Amivantamab Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Amivantamab Revenue in 2021
3.3 Global Amivantamab Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Amivantamab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Amivantamab Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Product Specification
4.1 Global Amivantamab Sales by Product Specification
4.1.1 Global Amivantamab Historical Sales by Product Specification (2017-2022)
4.1.2 Global Amivantamab Forecasted Sales by Product Specification (2023-2028)
4.1.3 Global Amivantamab Sales Market Share by Product Specification (2017-2028)
4.2 Global Amivantamab Revenue by Product Specification
4.2.1 Global Amivantamab Historical Revenue by Product Specification (2017-2022)
4.2.2 Global Amivantamab Forecasted Revenue by Product Specification (2023-2028)
4.2.3 Global Amivantamab Revenue Market Share by Product Specification (2017-2028)
4.3 Global Amivantamab Price by Product Specification
4.3.1 Global Amivantamab Price by Product Specification (2017-2022)
4.3.2 Global Amivantamab Price Forecast by Product Specification (2023-2028)
5 Market Size by Application
5.1 Global Amivantamab Sales by Application
5.1.1 Global Amivantamab Historical Sales by Application (2017-2022)
5.1.2 Global Amivantamab Forecasted Sales by Application (2023-2028)
5.1.3 Global Amivantamab Sales Market Share by Application (2017-2028)
5.2 Global Amivantamab Revenue by Application
5.2.1 Global Amivantamab Historical Revenue by Application (2017-2022)
5.2.2 Global Amivantamab Forecasted Revenue by Application (2023-2028)
5.2.3 Global Amivantamab Revenue Market Share by Application (2017-2028)
5.3 Global Amivantamab Price by Application
5.3.1 Global Amivantamab Price by Application (2017-2022)
5.3.2 Global Amivantamab Price Forecast by Application (2023-2028)
6 North America
6.1 North America Amivantamab Market Size by Product Specification
6.1.1 North America Amivantamab Sales by Product Specification (2017-2028)
6.1.2 North America Amivantamab Revenue by Product Specification (2017-2028)
6.2 North America Amivantamab Market Size by Application
6.2.1 North America Amivantamab Sales by Application (2017-2028)
6.2.2 North America Amivantamab Revenue by Application (2017-2028)
6.3 North America Amivantamab Market Size by Country
6.3.1 North America Amivantamab Sales by Country (2017-2028)
6.3.2 North America Amivantamab Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Amivantamab Market Size by Product Specification
7.1.1 Europe Amivantamab Sales by Product Specification (2017-2028)
7.1.2 Europe Amivantamab Revenue by Product Specification (2017-2028)
7.2 Europe Amivantamab Market Size by Application
7.2.1 Europe Amivantamab Sales by Application (2017-2028)
7.2.2 Europe Amivantamab Revenue by Application (2017-2028)
7.3 Europe Amivantamab Market Size by Country
7.3.1 Europe Amivantamab Sales by Country (2017-2028)
7.3.2 Europe Amivantamab Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Amivantamab Market Size by Product Specification
8.1.1 Asia Pacific Amivantamab Sales by Product Specification (2017-2028)
8.1.2 Asia Pacific Amivantamab Revenue by Product Specification (2017-2028)
8.2 Asia Pacific Amivantamab Market Size by Application
8.2.1 Asia Pacific Amivantamab Sales by Application (2017-2028)
8.2.2 Asia Pacific Amivantamab Revenue by Application (2017-2028)
8.3 Asia Pacific Amivantamab Market Size by Region
8.3.1 Asia Pacific Amivantamab Sales by Region (2017-2028)
8.3.2 Asia Pacific Amivantamab Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Amivantamab Market Size by Product Specification
9.1.1 Latin America Amivantamab Sales by Product Specification (2017-2028)
9.1.2 Latin America Amivantamab Revenue by Product Specification (2017-2028)
9.2 Latin America Amivantamab Market Size by Application
9.2.1 Latin America Amivantamab Sales by Application (2017-2028)
9.2.2 Latin America Amivantamab Revenue by Application (2017-2028)
9.3 Latin America Amivantamab Market Size by Country
9.3.1 Latin America Amivantamab Sales by Country (2017-2028)
9.3.2 Latin America Amivantamab Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Amivantamab Market Size by Product Specification
10.1.1 Middle East and Africa Amivantamab Sales by Product Specification (2017-2028)
10.1.2 Middle East and Africa Amivantamab Revenue by Product Specification (2017-2028)
10.2 Middle East and Africa Amivantamab Market Size by Application
10.2.1 Middle East and Africa Amivantamab Sales by Application (2017-2028)
10.2.2 Middle East and Africa Amivantamab Revenue by Application (2017-2028)
10.3 Middle East and Africa Amivantamab Market Size by Country
10.3.1 Middle East and Africa Amivantamab Sales by Country (2017-2028)
10.3.2 Middle East and Africa Amivantamab Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 ProteoGenix
11.1.1 ProteoGenix Corporation Information
11.1.2 ProteoGenix Overview
11.1.3 ProteoGenix Amivantamab Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 ProteoGenix Amivantamab Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 ProteoGenix Recent Developments
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Corporation Information
11.2.2 Thermo Fisher Scientific Overview
11.2.3 Thermo Fisher Scientific Amivantamab Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Thermo Fisher Scientific Amivantamab Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Thermo Fisher Scientific Recent Developments
11.3 AntibodySystem SAS
11.3.1 AntibodySystem SAS Corporation Information
11.3.2 AntibodySystem SAS Overview
11.3.3 AntibodySystem SAS Amivantamab Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 AntibodySystem SAS Amivantamab Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 AntibodySystem SAS Recent Developments
11.4 Wuhan Chemstan Biotechnology
11.4.1 Wuhan Chemstan Biotechnology Corporation Information
11.4.2 Wuhan Chemstan Biotechnology Overview
11.4.3 Wuhan Chemstan Biotechnology Amivantamab Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Wuhan Chemstan Biotechnology Amivantamab Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Wuhan Chemstan Biotechnology Recent Developments
11.5 Biochempartner
11.5.1 Biochempartner Corporation Information
11.5.2 Biochempartner Overview
11.5.3 Biochempartner Amivantamab Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Biochempartner Amivantamab Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Biochempartner Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Amivantamab Industry Chain Analysis
12.2 Amivantamab Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Amivantamab Production Mode & Process
12.4 Amivantamab Sales and Marketing
12.4.1 Amivantamab Sales Channels
12.4.2 Amivantamab Distributors
12.5 Amivantamab Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Amivantamab Industry Trends
13.2 Amivantamab Market Drivers
13.3 Amivantamab Market Challenges
13.4 Amivantamab Market Restraints
14 Key Findings in The Global Amivantamab Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer